Mizuho reiterates Establishment Labs stock rating on strong sales
Mizuho reiterated an Outperform rating and $105 price target for Establishment Labs (ESTA) after its Q3 results. The company beat revenue estimates by $5M, with U.S. sales up 4% YoY and international sales up 10% YoY. ESTA raised 2026 revenue guidance to over $274M. Q3 revenue grew 34% YoY to $72M, but EPS loss of $0.35 missed estimates. BTIG lowered its price target to $93 but maintained a Buy rating.
How this was made
The 30-second read
Why it matters
The earnings beat and upgraded guidance provide a fresh catalyst that could drive the stock higher in the short term.
Market read
The new earnings data and guidance revisions are the primary drivers of relevance for traders.
What to watch
Seasonal decline in global minimally invasive sales and modest absolute revenue size could temper upside.
Background
ESTABLISHMENT LABS reported Q3 revenue of $72.0 million, beating estimates, posted a loss of $0.35 per share, and achieved its first free‑cash‑flow‑positive quarter. Mizuho raised its price target to $105 and reaffirmed Outperform.
Ticker impact
Mizuho reiterated an Outperform rating and $105 price target on ESTABLISHMENT LABS after its Q3 results and raised 2026 revenue guidance.
likely upward pressure as the market prices in the higher target and guidance.
The fresh earnings beat, first‑ever free cash flow positive quarter, and raised guidance provide new positive catalysts.
Market effects
Positive earnings and guidance may lift the broader medical‑device and minimally invasive surgery sector.
U.S. investors may see modest buying pressure in small‑cap biotech/med‑device space.
Limited to investors tracking U.S. listed med‑device stocks.
Counterpoint
The company remains loss‑making and valuation may still be stretched despite the upgrade.
Key entities
- analystMizuho
Reiterated Outperform rating and raised price target.
- analystBTIG
Adjusted price target to $93, maintaining Buy rating.
